After Taxotere fails, treatment options for metastatic prostate cancer are limited.
The three drugs with FDA approval in this setting, Jevtana, Provenge and Zytiga, are associated with median survivals of less than 2 years. In part, the impact on survival is the result of low response rates, indicating a significant proportion of patients exhibiting de novo resistance to these agents. An alternate approach is to let treatment selection be governed by gene expression profiling so that the treatment is tailored to the specific patient. Here, we report a case of metastatic prostate cancer with a dramatic response to treatment selected based on molecular profiling. This patient had failed LHRH agonist, bicalutamide, Taxotere, and doxorubicin. Molecular profiling showed overexpression of the androgen receptor and he had a dramatic response of measurable disease to second-line hormonal therapy with ketoconazole, estrogen and Leukine.
Written by:
Myers CE, Basu G, Wright B, Mahanes J, Spinelli A Are you the author?
Foundation for Cancer Research and Education, Earlysville, Charlottesville, Va., USA
Reference: Case Rep Oncol. 2012 Jan;5(1):154-8
doi: 10.1159/000338077
PubMed Abstract
PMID: 22666205